Livagen

Livagen (Lys–Glu–Asp–Ala) is described as a short ‘bioregulatory’ tetrapeptide studied mainly in vitro and in animal models for two related themes: peptidase inhibition and age-linked gene regulation. In the protocol’s mechanism section, Livagen strongly inhibits enzymes that break down enkephalins in human serum, which may prolong endogenous enkephalin signaling without directly binding opioid receptors. Separately, the page highlights epigenetic-style effects observed in aging cells, including heterochromatin decondensation and reactivation of ribosomal gene activity—findings presented as potential markers of improved cellular function in older tissues. Additional preclinical work referenced includes organ-culture studies in rat liver suggesting improved cellular structure and regeneration signals, plus rodent data showing shifts in digestive-enzyme activity toward more “youthful” patterns. The protocol notes that human dosing standards are not established and that current use is investigational and extrapolated from this preclinical evidence base.